Seegene

Seegene EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Seegene (096530.KQ) as of Nov 7, 2026 is 30.50. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -23.71 — a change of -228.61% (higher).

EV/EBIT

30.50

YoY

-228.61%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Seegene is 2025 30.50 . EV/EBIT (Enterprise Value to EBIT) of Seegene was 2024 -23.71 . It decreases by -228.61% higher compared to the previous year.

The Seegene EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
45.38 KRW
Jan 1, 2020
1.56 KRW
Jan 1, 2021
1.58 KRW
Jan 1, 2022
5.37 KRW
Jan 1, 2023
-35.65 KRW
Jan 1, 2024
-23.71 KRW
Jan 1, 2025
30.50 KRW
Jan 1, 2026 (e)
9.21 KRW
The Seegene EV/EBIT history
YEAREV/EBITYoY
est9.21-69.80%
30.50-228.61%
-23.71-33.50%
-35.65-764.25%
5.37+239.60%
1.58+1.33%
1.56-96.56%
45.38-55.49%
101.96-51.33%
209.48+93.18%
108.44-18.91%
133.73+41.13%
94.76+38.55%
68.39-16.14%
81.55-15.38%
96.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Seegene Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Seegene's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Seegene's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Seegene's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Seegene grows earnings faster than its peers.

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

EV/EBIT (Enterprise Value to EBIT) of Seegene is 30.50 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Seegene changed from -23.71 to 30.50, representing a -228.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Seegene since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Seegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Seegene

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Seegene